# Definium Therapeutics Inc. (DFTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $38.09, market value $5.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Definium Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.6×**. The shares trade at 5.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -55.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -33.8%**. Earnings per share fell 33.8%.

## Financial health
- **Debt to equity: 0.12**. Debt is 0.12 times equity: a conservative balance sheet.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Definium Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (17 analysts). 17 analysts cover Definium Therapeutics Inc.; the consensus is strong_buy, with an average price target of $67.47 (+77% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 312.7%** (YTD 184.5%, 3-mo 61.7%). The shares are up 312.7% over twelve months including dividends.
- **From 52-week high: -23.4%** (334.2% above the low). Trading 23% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 37**. An RSI of 37 is neutral.
- **Beta (1 yr): 1.09** (volatility 80%). Beta of 1.09 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DFTX · Page: https://foliofundamentals.com/stocks/dftx

Not investment advice.